David Revcolevschi - McDermott Will & Emery

Overview


David Revcolevschi focuses his practice on French and international securities offerings, mergers and acquisitions, and more generally on the securities and corporate law and corporate governance issues faced by publicly listed companies.

David has extensive experience in equity and equity-linked securities offerings, representing issuers, underwriters, and shareholders. He has notably advised on more than 35 IPO projects on Euronext Paris, Nasdaq, the Hong Kong Stock Exchange and the London Stock Exchange and numerous other securities issuances by companies operating in the life science (biotechnology, medical device), technology (software, hardware, telecom), airlines, aerospace, real estate, leisure and entertainment, chemicals, utilities and financial sectors.

Show More

Results


Equity Capital Markets Transactions

  • Advised Poxel (Biotech, France, Euronext Growth) on an equity-linked financing by Iris Capital in connection with the restructuring of its debt facility with IPF (2022)
  • Advised Aelis Pharma (Biotech, France) on its IPO on Euronext Paris (2022)
  • Advised GeNeuro (Biotech, Switzerland, Euronext Paris) on an international private placement of new shares (2022)
  • Advised Acticor Biotech (Biotech, France) on its IPO on Euronext Growth Paris (2021)
  • Advised Genkyotex (Biotech, France, Euronext Paris and Brussels) on the squeeze-out and public buyout (OPRO-RO) in cash and CVRs by Calliditas Therapeutics (Sweden, Stockholm and Nasdaq) (2021)
  • Advised AMA Corporation (Augmented reality technology, France) on its IPO on Euronext Growth Paris (2021)
  • Advised H.C.W. Wainwright, acting as placement agent, in connection with the issuance of shares with warrants (ABSA) by Pixium (Biotech, Euronext Growth Paris) (2021)
  • Advised GeNeuro (Biotech, Switzerland, Euronext Paris) on an international private placement of new shares (2021)
  • Advised H.C.W. Wainwright, acting as placement agent, in connection with the issuance of shares with warrants (ABSA) by Erytech (Biotech, Euronext Paris) (from May to November 2021)

Show More

Recognitions


  • Best Lawyers in France, Capital Markets Law, 2010-2025
  • The Legal 500 EMEA, Recommended Lawyer, 2008-2023
  • IFLR1000, Capital Markets: Equity, M&A, 2008-2023
  • Chambers Europe, 2006-2012, 2018
  • Chambers Global, 2007-2012, 2018
  • The Legal Media Group Expert Guides, Capital Markets 2008-2020

Credentials


Education
Harvard Law School, Graduate Program, Fulbright Scholar, 1997-1998
University of Paris I (Panthéon-Sorbonne), Master’s degree in Business Law (Magistère), 1996
University of Paris I (Panthéon-Sorbonne), Master’s degrees in Public Law (DEA), 1996
University of Paris I (Panthéon-Sorbonne), Master’s degrees in the History of International Relations (DEA), 1995

Admissions
Paris

Languages
English
French